Impact of drug industry mergers is still uncertain

Article Abstract:

Opinions vary on how heightened merger and acquisition activity in the pharmaceutical industry will affect prices, competition and product development. Some see an environment characterized by less choice and higher prices. Others see the cost efficiencies from consolidation as promoting the switch from high-price prescription drugs to low-price over-the-counter generics. Still, it is unlikely research will be sacrificed for low-stakes generic competition.

---

Glaxo bids $15 billion to buy Wellcome, maker of AZT

Article Abstract:

Glaxo PLC wants to buy Wellcome PLC for $15 billion. The deal would be the biggest in the industry and would result in a company having a global market share of 5.3%, which would make it the largest in the world. Glaxo's bid is seen by analysts as an attempt to diversify its product line and cut costs, as well as access Wellcome expertise in antiviral research. Wellcome, the manufacturer of AZT, is hoping for an offer from another source.

Glaxo Holdings PLC, Wellcome PLC

---

Drugmaker launches first foray into providing care

Article Abstract:

Zeneca Ltd, a UK-based international pharmaceutical firm with sales of $6.5 billion in 1994, acquired Salick Health Care Inc, based in Los Angeles, CA, which provides dialysis and other medical services in the US. The Apr 1995 purchase may be the first of many drug company acquisitions including managed care providers and doctors' practices. Ethical considerations arise if physicians are pressured to prescribe the company's drugs.

HEALTH SERVICES, Medical Services NEC, Other Ambulatory Health Care Services, Health care industry, Medical care, Zeneca Ltd., Salick Health Care Inc., SHCI

Similar abstracts:

• Abstracts: Searle joins in pushing managed care for the elderly. Drug firms expand into patient care. HMO putting more control into physicians' hands
• Abstracts: West meets east: Philadelphia HMOs follow California into price war. HMOs bullish on Wall Street: megamerger of two public plans spurs new interest in stock offerings
• Abstracts: PHOs face obstacles under new antitrust standards. Nevada doctors launch managed care medical society. More doctors on PHO boards

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.